Bioengineers shed light on dosing challenges for cancer immunotherapy
A team of bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) -- a potent immune-boosting protein that holds promise for cancer treatment -- loses effectiveness over time when used as an immunotherapeutic. The research challenges long-held assumptions about IL-12 s behavior in the body and offers a path toward safer and more effective dosing regimens.
admin
0
1
A team of bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) -- a potent immune-boosting protein that holds promise for cancer treatment -- loses effectiveness over time when used as an immunotherapeutic. The research challenges long-held assumptions about IL-12 s behavior in the body and offers a path toward safer and more effective dosing regimens.
